Drugs / Bevonescein
Bevonescein
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04420689 | Jun 2020 → Jun 2021 | nervous system injury, parotid gland neoplasm, thyroid tumor | Alume Biosciences, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07631650 | Jun 2026 → Aug 2027 expected | head and neck cancer | Matthew Spector | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06662097 | Oct 2024 → Jun 2025 overdue | nervous system injury | Alume Biosciences, Inc. | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06227585 | Nov 2023 → Oct 2025 | — | Alume Biosciences, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05377554 | Apr 2022 → Oct 2025 | — | Alume Biosciences, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bevonescein | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04420689 ↗ |
| Known as | ALM 488 | “Bevonescein (ALM 488) Infusion” NCT07631650 ↗ |
| Known as | Bevonesceina | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095488 ↗ |
| Known as | Bevonesceine | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095488 ↗ |
| Modality | Peptide | “synthetic, peptide dye conjugate” NCT04420689 ↗ |
| Route | Intravenous | “administered as an intravenous (IV) infusion” NCT04420689 ↗ |